A Phase I/IIb, randomized, controlled study evaluating atezolizumab in combination with the BEGEV regimen as a first-line salvage treatment in patients with relapsed or refractory Hodgkin lymphoma who are eligible for autologous stem cell transplantation.
Principal Investigator
Dott.ssa Delia Rota Scalabrini
Contact Information for Access
Phase
FASE II
Status
ATTIVO
Objective of the study
The purpose of the study is to determine the maximum tolerated dose of atezolizumab in combination with the BEGEV regimen, established during the first cycle of therapy, in order to subsequently determine the dose of atezolizumab in the second phase following transplantation.
ClinicalTrials.gov ID NCT05929222
Sponsor: Italian Lymphoma Foundation - ETS
Pathologies
Onco-hematological (hematological cancers/malignancies)
Medication
Atezolizumab: anti-PD-L1 monoclonal antibody;
BEGEV regimen: Chemotherapy regimen with gemcitabine, bendamustine, and vinorelbine.
Who is eligible to participate in the study?
Patients who are 18 years of age or older and who meet the study’s eligibility criteria may participate in this study.
Diagnosis of Refractory or Relapsed Hodgkin Lymphoma
View the full study Back to search page